MTOR and hepatocellular carcinoma: Next-generation sequencing (NGS) of 127 HCC patients, 87 of whom received sorafenib treatment, identified activating mutations in the PI3K/mTOR pathway as a determinant of shorter median PFS and OS in sorafenib treatment [45].